Lung Cancer Pathology: Key Insights for Early Detection

Lung cancer pathology remains a global health challenge. It is the most common cause of cancer incidence and mortality among men and a leading cause of cancer deaths among women. Despite advances in prevention and treatment, early detection remains the base for improving outcomes. Pathologists are indispensable. They identify and classify lung cancer, particularly its early stages. This blog explores key insights into lung cancer pathology, focusing on early detection.

The Epidemiology of Lung Cancer

Worldwide, lung cancer pathology is the most common cause of cancer-related mortality in men and ranks second in women. In the United States, the American Cancer Society estimated over 222,000 new cases of lung cancer pathology and more than 157,000 related deaths in 2010.
While lung cancer incidence in men has declined since the 1980s, it has plateaued among women. Early detection strategies and accurate pathological classification are essential to address this burden effectively.

The Role of Pathology in Early Detection

Pathological evaluation is the foundation of lung cancer pathology diagnosis. A lung pathology report is generated after analysing tissue samples obtained through biopsies or cytology. These reports provide:
Pre-cancerous conditions: These include atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), and squamous dysplasia. Early identification of these lesions can prevent progression to invasive pulmonary cancer pathology.
Cancer types and subtypes: Accurate classification of lung cancer pathology—whether non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC).
Staging and molecular insights: A lung cancer report often includes tumour size, invasion depth, and molecular markers.

Advances in Lung Cancer Classification

The 2011 IASLC/ATS/ERS classification of lung cancer pathology introduced significant updates, superseding the 2004 WHO classification. These changes are especially impactful for small biopsy and cytology specimens.

Pre-invasive lesions

• Atypical adenomatous hyperplasia (AAH): A small, focal proliferation of atypical epithelial cells along alveoli and respiratory bronchioles (bronchial adenoma). AAH can progress to AIS or invasive pulmonary cancer pathology.
• Adenocarcinoma in situ (AIS): Defined as a small (≤3 cm) lepidic tumour with no invasive components. Complete resection often results in 100% five-year disease-free survival for lung tumour pathology.

New subtypes of invasive adenocarcinoma

The classification emphasises histological patterns (e.g., lepidic, acinar, papillary, micropapillary, and solid) with distinct prognostic implications. For instance, micropapillary adenocarcinoma is associated with poor outcomes in lung cancer pathology.

Small biopsies and cytology

Comprehensive histologic subtyping is encouraged. Immunohistochemistry plays a pivotal role in distinguishing between adenocarcinoma and squamous cell carcinoma.

Pre-Cancerous Lesions: Opportunities for Early Detection

Squamous dysplasia and carcinoma in situ (CIS):

• Squamous dysplasia progresses through mild, moderate, and severe stages, culminating in CIS. Pathological examination reveals cytologic atypia and thickness abnormalities in the bronchial epithelium for lung cancer pathology.
• Molecular changes like p53 mutation and VEGF overexpression accompany histologic progression in lung cancer pathology.

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH):

• A rare condition involving neuroendocrine cell hyperplasia and tumours, DIPNECH is considered a precursor to carcinoid tumours. It typically presents as multiple pulmonary nodules or airway obstruction.

Diagnostic Techniques and Molecular Insights

1. Histologic and Cytologic Evaluation:
Small biopsies and cytology specimens are vital for diagnosing advanced-stage lung cancer. Morphologic features differentiate between major types like adenocarcinoma and squamous cell lung carcinoma.

2. Immunohistochemistry (IHC):

• IHC markers like TTF-1 and napsin A identify adenocarcinoma, while p40 and p63 are specific for squamous cell lung carcinoma.
• The calretinin marker may be useful in differentiating mesothelioma from lung adenocarcinoma or squamous carcinoma.

3. Molecular Testing:

• Tests for EGFR mutations, ALK rearrangements, and PD-L1 expression are now standard for guiding targeted therapies and immunotherapy.
• EGFR mutation testing is recommended for adenocarcinoma, NSCLC favouring adenocarcinoma and NSCLC-NOS diagnoses.

4. Lung cancer biopsy techniques:

• Lung cancer biopsy procedures are critical for obtaining adequate histological evaluation and molecular testing samples. For example, fine-needle aspiration and core needle biopsy.

5. Minimising Tissue Use:

• Pathologists prioritise efficient tissue management to preserve material for molecular studies. Cutting multiple unstained slides during initial processing can help maximise diagnostic and molecular testing opportunities.

Implications of Updated Classifications

The refined classification system has profound implications for therapy and prognosis:

NSCLC Subtyping:

• Precise subtyping influences eligibility for targe
• ted therapies, such as EGFR tyrosine kinase inhibitors for adenocarcinoma.
• Differentiating squamous cell carcinoma from adenocarcinoma is critical, as certain treatments (e.g., pemetrexed and bevacizumab) are contraindicated for squamous cell carcinoma in pulmonary cancer pathology.

Prognostic Value:
Tumours with predominant lepidic patterns (e.g., AIS or MIA) have excellent survival rates, while solid or micropapillary patterns indicate poorer outcomes in lung cancer pathology.

Lung lesions and staging considerations:
Comprehensive histologic subtyping aids in distinguishing synchronous primaries from metastases, impacting TNM staging and treatment planning in lung tumour pathology.

Final Words

Lung cancer pathology has advanced. Lung cancer pathology classification is well-defined today. There is innovation in diagnostic and molecular testing techniques. Yet, pathologists play a vital role in early detection. They must stay abreast of classification updates and employ state-of-the-art diagnostic tools for pulmonary cancer identification. It is the most important part of treating the disease.